GU Cancers 2019 | Real-world vs. clinical trial: efficacy of nivolumab in mRCC

Ugo De Giorgi

Data from clinical studies often differs from real-world data, as trials conduct research based on a narrowly defined, homogenous patient population. CheckMate 025 (NCT01668784) is a randomized, Phase III trial looking at the efficacy of nivolumab in metastatic renal cell carcinoma (mRCC). Although promising results were seen with the drug, the limitation of the study lay with the highly selective criteria for patient enrollment. Ugo De Giorgi, MD, PhD, of the IRCCS, Meldola, Italy, talks about the Italian renal cell cancer (RCC) expanded access program, which evaluated the safety and efficacy of nivolumab in mRCC in a real-world setting. This video was taken at the 2019 Genitourinary Cancers Symposium, held in San Francisco, CA.

Share this video